Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 11/20 | 0.46 |
| ▸ | CDC7 | O00311 | 4/20 | 0.46 |
| ▸ | PIM1 | P11309 | 3/20 | 0.46 |
| ▸ | HIPK2 | Q9H2X6 | 3/20 | 0.46 |
| ▸ | CLK4 | Q9HAZ1 | 3/20 | 0.46 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.46 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.46 |
| ▸ | PRKACA | P17612 | 2/20 | 0.46 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.43 |
| ▸ | PSD | A5PKW4 | 1/20 | 0.39 |
| ▸ | CDK2 | P24941 | 2/20 | 0.38 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | GLA | P06280 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | MPI | P34949 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL909871 | 0.84 | GSK3B (0.48) | GSK3BCDC7PIM1HIPK2CLK4 | |
| SCHEMBL910226 | 0.82 | GSK3B (0.58) | GSK3BCDC7PIM1HIPK2CLK4 | |
| SCHEMBL12904336 | 0.79 | GSK3B (0.46) | GSK3BCDC7PIM1HIPK2CLK4 | |
| SCHEMBL910170 | 0.79 | GSK3B (0.50) | GSK3BCDC7PIM1HIPK2CLK4 | |
| SCHEMBL1832862 | 0.79 | GSK3B (0.44) | GSK3BCDC7PIM1HIPK2CLK4 | |
| SCHEMBL1835974 | 0.79 | PSEN1 (0.45) | GSK3BCDC7PIM1HIPK2CLK4 | |
| SCHEMBL1841387 | 0.78 | GSK3B (0.58) | GSK3BCDC7PIM1HIPK2CLK4 | |
| SCHEMBL1839402 | 0.77 | PRKDC (0.54) | GSK3BCDC7PIM1HIPK2CLK4 | |
| SCHEMBL1835853 | 0.77 | GSK3B (0.39) | GSK3BCDC7PIM1HIPK2CLK4 | |
| SCHEMBL1840545 | 0.77 | GSK3B (0.44) | GSK3BCDC7PIM1HIPK2CLK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7872011-B2 | Inhibition of phosphoinositide 3-kinase β | ASTRAZENECA AB (SE) | 2011-01-18 | — | — | US | disclosed |
| US-7598377-B2 | (+-)-7-Methyl-2-morpholin-4-yl-9-(1-phenylaminoethyl)-pyrido[1,2-a]pyrimidin-4-one, for example; selective inhibitors of phosphoinositide (PI) 3-kinase beta for use in anti-thrombotic therapy | ASTRAZENECA AB (SE) | 2009-10-06 | — | — | US | disclosed |
| US-20080319021-A1 | Inhibition Of Phosphoinositide 3-Kinase Beta | KINACIA PTY. LTD. (AU) | 2008-12-25 | — | — | US | disclosed |
| US-20060276470-A1 | (+-)-7-Methyl-2-morpholin-4-yl-9-(1-phenylaminoethyl)-pyrido[1,2-a]pyrimidin-4-one, for example; selective inhibitors of phosphoinositide (PI) 3-kinase beta for use in anti-thrombotic therapy | ASTRAZENECA AB (SE) | 2006-12-07 | — | — | US | disclosed |
| EP-1537102-A1 | INHIBITION OF PHSPHOINOSTIDE 3-DINASE BETA | Kinacia Pty Ltd. (AU) | 2005-06-08 | — | — | EP | disclosed |
| WO-2004016607-A1 | INHIBITION OF PHOSPHOINOSITIDE 3-KINASE BETA | KINACIA PTY LTD. (AU) | 2004-02-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080319021-A1 | Inhibition Of Phosphoinositide 3-Kinase Beta | PI4KB, PI4KA, PI4K2B | GSK3B 67/4885CDC7 188/4885PIM1 360/4885 |
| US-20060276470-A1 | (+-)-7-Methyl-2-morpholin-4-yl-9-(1-phenylaminoethyl)-pyrido[1,2-a]pyrimidin-4-one, for example; selective inhibitors of phosphoinositide (PI) 3-kinase beta for use in anti-thrombotic therapy | PI4KA, PI4KB, PI4K2B | GSK3B 253/4885CDC7 232/4885PIM1 254/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.